olaparib-话题@MedSci - 梅斯（MedSci）

#olaparib#

14篇内容 | 1217人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1633990, encodeId=fa83163399029, content=<a href='/topic/show?id=9f0313304b2' target=_blank style='color:#2F92EE;'>#olaparib#</a>, objectTitle=Clin Cancer Res: Olaparib(奥拉帕利)单药维持治疗亚洲人群铂敏感复发卵巢癌的疗效：III期临床研究L-MOCA, objectType=article, longId=295346, objectId=6f04295346b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f04295346b6, replyNumber=0, likeNumber=71, createdTime=2022-06-11, rootId=0, userName=刘阔, userId=ffe222060531, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f04295346b6, moduleTitle=Clin Cancer Res: Olaparib(奥拉帕利)单药维持治疗亚洲人群铂敏感复发卵巢癌的疗效：III期临床研究L-MOCA, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=6f04295346b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1633988, encodeId=1eb6163398836, content=<a href='/topic/show?id=9f0313304b2' target=_blank style='color:#2F92EE;'>#olaparib#</a>, objectTitle=ASCO GU 2021: ctDNA检测能有效判断Olaparib对去势抵抗性前列腺癌效果（PROfound研究）, objectType=article, longId=207230, objectId=677220e230b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=677220e230b0, replyNumber=0, likeNumber=82, createdTime=2022-01-18, rootId=0, userName=刘阔, userId=ffe222060531, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=677220e230b0, moduleTitle=ASCO GU 2021: ctDNA检测能有效判断Olaparib对去势抵抗性前列腺癌效果（PROfound研究）, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=677220e230b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1633989, encodeId=503a16339897d, content=<a href='/topic/show?id=9f0313304b2' target=_blank style='color:#2F92EE;'>#olaparib#</a>, objectTitle=Br J Cancer：Olaparib奥拉帕尼联合半胸放疗提高肺癌的治疗指数, objectType=article, longId=208933, objectId=66cb208933a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=66cb208933a5, replyNumber=0, likeNumber=93, createdTime=2022-02-18, rootId=0, userName=刘阔, userId=ffe222060531, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=66cb208933a5, moduleTitle=Br J Cancer：Olaparib奥拉帕尼联合半胸放疗提高肺癌的治疗指数, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=66cb208933a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1633987, encodeId=e437163398e8e, content=<a href='/topic/show?id=9f0313304b2' target=_blank style='color:#2F92EE;'>#olaparib#</a>, objectTitle=LYNPARZA（olaparib）联合贝伐单抗一线治疗HRD阳性晚期卵巢癌：已获FDA首肯, objectType=article, longId=193965, objectId=a65b19396562, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a65b19396562, replyNumber=0, likeNumber=73, createdTime=2020-08-05, rootId=0, userName=刘阔, userId=ffe222060531, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a65b19396562, moduleTitle=LYNPARZA（olaparib）联合贝伐单抗一线治疗HRD阳性晚期卵巢癌：已获FDA首肯, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=a65b19396562)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1633985, encodeId=62b51633985c8, content=<a href='/topic/show?id=9f0313304b2' target=_blank style='color:#2F92EE;'>#olaparib#</a>, objectTitle=NEJM：Olaparib为有BRCA突变的转移性乳腺癌患者带来希望, objectType=article, longId=108450, objectId=b39c1084500d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b39c1084500d, replyNumber=0, likeNumber=76, createdTime=2018-06-17, rootId=0, userName=刘阔, userId=ffe222060531, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b39c1084500d, moduleTitle=NEJM：Olaparib为有BRCA突变的转移性乳腺癌患者带来希望, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=b39c1084500d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1633984, encodeId=f95916339843e, content=<a href='/topic/show?id=9f0313304b2' target=_blank style='color:#2F92EE;'>#olaparib#</a>, objectTitle=卵巢癌新药olaparib获3期临床突破, objectType=article, longId=92108, objectId=5ff2921087a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ff2921087a, replyNumber=0, likeNumber=78, createdTime=2018-01-22, rootId=0, userName=刘阔, userId=ffe222060531, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ff2921087a, moduleTitle=卵巢癌新药olaparib获3期临床突破, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=5ff2921087a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1633986, encodeId=39dd1633986dc, content=<a href='/topic/show?id=9f0313304b2' target=_blank style='color:#2F92EE;'>#olaparib#</a>, objectTitle=NEJM：BRCA生殖系突变阳性的晚期乳腺癌：奥拉帕尼（Olaparib）有力回天？, objectType=article, longId=108612, objectId=fcb31086129c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fcb31086129c, replyNumber=0, likeNumber=115, createdTime=2018-06-07, rootId=0, userName=刘阔, userId=ffe222060531, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fcb31086129c, moduleTitle=NEJM：BRCA生殖系突变阳性的晚期乳腺癌：奥拉帕尼（Olaparib）有力回天？, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=fcb31086129c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1633983, encodeId=bff916339831b, content=<a href='/topic/show?id=9f0313304b2' target=_blank style='color:#2F92EE;'>#olaparib#</a>, objectTitle=ASCO 2016：奥拉帕利（Olaparib）全面开战：卵巢癌、乳腺癌、胃癌, objectType=article, longId=70433, objectId=5298e043346, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5298e043346, replyNumber=0, likeNumber=69, createdTime=2016-11-13, rootId=0, userName=刘阔, userId=ffe222060531, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5298e043346, moduleTitle=ASCO 2016：奥拉帕利（Olaparib）全面开战：卵巢癌、乳腺癌、胃癌, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=5298e043346)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1633982, encodeId=ef2416339822b, content=<a href='/topic/show?id=9f0313304b2' target=_blank style='color:#2F92EE;'>#olaparib#</a>, objectTitle=【ASCO 2016】预告：奥拉帕利（Olaparib）和BRCA突变相关研究, objectType=article, longId=69354, objectId=61d4693540e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=61d4693540e, replyNumber=0, likeNumber=65, createdTime=2016-07-27, rootId=0, userName=刘阔, userId=ffe222060531, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=61d4693540e, moduleTitle=【ASCO 2016】预告：奥拉帕利（Olaparib）和BRCA突变相关研究, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=61d4693540e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1633981, encodeId=6dbe1633981db, content=<a href='/topic/show?id=9f0313304b2' target=_blank style='color:#2F92EE;'>#olaparib#</a>, objectTitle=AACR 2015：女性患者福音！Olaparib联合Carboplatin对卵巢、乳腺癌初显疗效, objectType=article, longId=49756, objectId=704249e564a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=704249e564a, replyNumber=0, likeNumber=88, createdTime=2016-02-22, rootId=0, userName=刘阔, userId=ffe222060531, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=704249e564a, moduleTitle=AACR 2015：女性患者福音！Olaparib联合Carboplatin对卵巢、乳腺癌初显疗效, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=704249e564a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1633979, encodeId=388516339e976, content=<a href='/topic/show?id=9f0313304b2' target=_blank style='color:#2F92EE;'>#olaparib#</a>, objectTitle=阿斯利康“死去”的抗癌药物Olaparib“复活”, objectType=article, longId=37141, objectId=ef013e1416c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ef013e1416c, replyNumber=0, likeNumber=85, createdTime=2015-05-04, rootId=0, userName=刘阔, userId=ffe222060531, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ef013e1416c, moduleTitle=阿斯利康“死去”的抗癌药物Olaparib“复活”, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=ef013e1416c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1633978, encodeId=87de16339e874, content=<a href='/topic/show?id=9f0313304b2' target=_blank style='color:#2F92EE;'>#olaparib#</a>, objectTitle=阿斯利康抗癌药olaparib上市之路坎坷不平, objectType=article, longId=37015, objectId=47733e0152d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=47733e0152d, replyNumber=0, likeNumber=88, createdTime=2015-06-02, rootId=0, userName=刘阔, userId=ffe222060531, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=47733e0152d, moduleTitle=阿斯利康抗癌药olaparib上市之路坎坷不平, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=47733e0152d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1633980, encodeId=23f9163398057, content=<a href='/topic/show?id=9f0313304b2' target=_blank style='color:#2F92EE;'>#olaparib#</a>, objectTitle=欧盟医药管理部门将表决是否加速阿斯利康卵巢癌药物olaparib审批流程, objectType=article, longId=41335, objectId=956741335b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=956741335b1, replyNumber=0, likeNumber=82, createdTime=2014-10-31, rootId=0, userName=刘阔, userId=ffe222060531, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=956741335b1, moduleTitle=欧盟医药管理部门将表决是否加速阿斯利康卵巢癌药物olaparib审批流程, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=956741335b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1633977, encodeId=581116339e770, content=<a href='/topic/show?id=9f0313304b2' target=_blank style='color:#2F92EE;'>#olaparib#</a>, objectTitle=阿斯利康启动olaparib III期SOLO项目, objectType=article, longId=24122, objectId=04fd241222d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04fd241222d, replyNumber=0, likeNumber=68, createdTime=2014-04-17, rootId=0, userName=刘阔, userId=ffe222060531, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04fd241222d, moduleTitle=阿斯利康启动olaparib III期SOLO项目, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=04fd241222d)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

olaparib

2020-05-29

刘阔 (审核中...)

前往app查看评论内容

#olaparib#

Clin Cancer Res: Olaparib(奥拉帕利)单药维持治疗亚洲人群铂敏感复发卵巢癌的疗效：III期临床研究L-MOCA

2022-06-11

刘阔 (审核中...)

前往app查看评论内容

#olaparib#

ASCO GU 2021: ctDNA检测能有效判断Olaparib对去势抵抗性前列腺癌效果（PROfound研究）

2022-01-18

刘阔 (审核中...)

前往app查看评论内容

#olaparib#

Br J Cancer：Olaparib奥拉帕尼联合半胸放疗提高肺癌的治疗指数

2022-02-18

刘阔 (审核中...)

前往app查看评论内容

#olaparib#

LYNPARZA（olaparib）联合贝伐单抗一线治疗HRD阳性晚期卵巢癌：已获FDA首肯

2020-08-05

刘阔 (审核中...)

前往app查看评论内容

#olaparib#

NEJM：Olaparib为有BRCA突变的转移性乳腺癌患者带来希望

2018-06-17

刘阔 (审核中...)

前往app查看评论内容

#olaparib#

卵巢癌新药olaparib获3期临床突破

2018-01-22

刘阔 (审核中...)

前往app查看评论内容

#olaparib#

NEJM：BRCA生殖系突变阳性的晚期乳腺癌：奥拉帕尼（Olaparib）有力回天？

2018-06-07

刘阔 (审核中...)

前往app查看评论内容

#olaparib#

ASCO 2016：奥拉帕利（Olaparib）全面开战：卵巢癌、乳腺癌、胃癌

2016-11-13

刘阔 (审核中...)

前往app查看评论内容

#olaparib#

【ASCO 2016】预告：奥拉帕利（Olaparib）和BRCA突变相关研究

2016-07-27

刘阔 (审核中...)

前往app查看评论内容

#olaparib#

AACR 2015：女性患者福音！Olaparib联合Carboplatin对卵巢、乳腺癌初显疗效

2016-02-22

刘阔 (审核中...)

前往app查看评论内容

#olaparib#

阿斯利康“死去”的抗癌药物Olaparib“复活”

2015-05-04

刘阔 (审核中...)

前往app查看评论内容

#olaparib#

阿斯利康抗癌药olaparib上市之路坎坷不平

2015-06-02

刘阔 (审核中...)

前往app查看评论内容

#olaparib#

欧盟医药管理部门将表决是否加速阿斯利康卵巢癌药物olaparib审批流程

2014-10-31

刘阔 (审核中...)

前往app查看评论内容

#olaparib#

阿斯利康启动olaparib III期SOLO项目

2014-04-17

科室
- - 订阅+
  - 更多科室
工具
服务